Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Olverembatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 69,387Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascentage Pharma Shares Innovation Strategy at J.P. Morgan Conf
    Ascentage Pharma Shares Innovation Strategy at J.P. Morgan Conf

    14 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/15/3219202/0/en/Ascentage-Pharma-Outlined-its-Global-Innovation-Strategy-During-Presentation-at-44th-Annual-J-P-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    14 Jan 2026
    Share Share
    In Diagnosed Ph+ ALL, Olverembatinib Yields >60% MRD-Neg CR Rate
    In Diagnosed Ph+ ALL, Olverembatinib Yields >60% MRD-Neg CR Rate

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202021/0/en/ASH-2025-Ascentage-Pharma-Presents-First-Dataset-from-Phase-III-POLARIS-1-Study-of-Olverembatinib-in-Newly-Diagnosed-Ph-ALL-Shows-a-Best-MRD-Negativity-CR-Rate-Exceeding-60.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share
    Ascentage Pharma Reveals 4-Year Data On Olverembatinib
    Ascentage Pharma Reveals 4-Year Data On Olverembatinib

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202022/0/en/ASH-2025-Ascentage-Pharma-Presents-Four-Year-Follow-Up-Data-from-Registrational-Phase-II-Study-of-Olverembatinib-Reaffirming-Differentiated-Long-Term-Efficacy-and-Safety-in-TKI-Res.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share
    Ascentage Pharma Update Olverembatinib Data In 2nd-Line Treatment
    Ascentage Pharma Update Olverembatinib Data In 2nd-Line Treatment

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202020/0/en/ASH-2025-Updated-Data-for-Ascentage-Pharma-s-Olverembatinib-in-Second-Line-CML-CP-Showing-Encouraging-Potential-for-Early-Line-Treatment.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share
    Ascentage Pharma Launches Global Phase 3 Trial of Olverembatinib
    Ascentage Pharma Launches Global Phase 3 Trial of Olverembatinib

    04 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/05/3200415/0/en/Ascentage-Pharma-Announces-Global-Registrational-Phase-III-Study-of-Olverembatinib-in-First-Line-Treatment-of-Ph-ALL-Cleared-by-US-FDA-and-EMA.html

    GLOBENEWSWIRE
    04 Dec 2025
    Share Share
    Ascentage Pharma Publishes Olverembatinib Phase Ib Data
    Ascentage Pharma Publishes Olverembatinib Phase Ib Data

    24 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/25/3193993/0/en/Ascentage-Pharma-Announces-Publication-of-Olverembatinib-Phase-Ib-Safety-Efficacy-and-Novel-Mechanism-Data-in-Gastrointestinal-Stromal-Tumors-in-Nature-s-Signal-Transduction-and-Ta.html

    GLOBENEWSWIRE
    24 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.